Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.

What the trial testedas reported · 50,452 people · 2019

Range includes no effect

+4%−6% to +15%

Bigger than 2 in 10 for adverse events & safety

As reported

OR 1.04, 95% CI 0.94–1.15

the abstract, start to end

… the use of GLP-1 receptor agonists (OR 1.04, 95% confidence interval (CI) …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

OR 1.040.94–1.15

GLP-1 receptor agonistsAdverse events & safety

GLP-1 receptor agonists × adverse events & safetyharms?mixed

unlikelylikely

0.00not counted

← favours treatmentfavours comparator →

more certainless certain

1 / 5

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it